GlassScriptPhysician profile
Helen H DO
NPI 1386034296
$5,048.79
in general payments reported to CMS, 2019-2025
41 companies · $890 in 2025
The $890 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,021 · 2022: $1,011 · 2023: $1,051 · 2024: $1,076 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,016.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,433.04 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.91 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $408.12 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Xeris Pharmaceuticals, INC. | $327.61 | 2024-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $200.80 | 2021-2023 | |
| Lilly USA, LLC | $190.30 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Dexcom, INC. | $181.39 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $164.48 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Almatica Pharma LLC | $141.26 | 2023-2025 | Loreev Xr |
| Gilead Sciences, INC. | $137.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $136.34 | 2021-2023 | Farxiga |
| Abbvie INC. | $129.21 | 2021-2025 | |
| Evofem Biosciences, INC. | $115.38 | 2021-2022 | |
| Redhill Biopharma INC. | $109.41 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Janssen Pharmaceuticals, INC | $94.00 | 2021-2023 | Spravato |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.